 |
 |
|
|
|
04/01/2012
Amylin reportedly turns down Bristol's $3.5B acquisition bid
Bristol-Myers Squibb offered to purchase Amylin Pharmaceuticals for $3.5 billion, sources said, but Amylin rejected the unsolicited bid. Analysts said Amylin, which makes diabetes medicines Byetta and Bydureon, might attract a bigger transaction from AstraZeneca or another company looking to augment its pipeline.
|
|
|
04/01/2012
Key Enzyme Involved in Protecting Nerves from Degeneration Identified
A new animal model of nerve injury has brought to light a critical role of an enzyme called Nmnat in nerve fiber maintenance and neuroprotection.
|
|
|
04/01/2012
GM Wheat Made to Scare Aphids
Field trials are now being done in England for a genetically modified (GM) wheat that scares away aphids and attracts a deadly predator to devour them, providing an alternative to insecticides that are presently used to control the pest.
|
|
|
|
